Kantarjian on Solutions for Oncology Drug Shortages
According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.
Ponatinib and Blinatumomab Demonstrates Durable Responses in PH+ ALL
Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
The Impact of Prominent Treatments in ALL
Hagop M. Kantarjian, MD, discusses the impact of prominent treatments in acute lymphoblastic leukemia.
Evolving Treatment Landscape of Acute Lymphocytic Leukemia
Hagop M. Kantarjian, MD, discusses how the treatment landscape of acute lymphocytic leukemia compares to what it used to be.
